Clinical Trial Update: Study of Panitumumab Efficacy in Patients With Recurrent and/or Metastatic Head and Neck Cancer [Phase 3]

View source ↗

Summary

Amgen completed a Phase 3 trial evaluating panitumumab for recurrent and/or metastatic head and neck cancer; trial results were posted in 2011.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Cancer

Drugs mentioned

• Panitumumab (panitumumab)

Snippet

Sponsor: Amgen | Conditions: Recurrent and/or Metastatic Head and Neck Cancer | Phase 3 | Status: COMPLETED | Results posted: 2011-06-14